Opinion
Video
Navigating HER2+ Brain Metastases: Emerging Insights
Experts share insights on cutting-edge data shaping HER2+ breast cancer care, from the paradigm-shifting HER2CLIMB trial to the promising TUXEDO-1 and ROSET-BD studies; they also uncover advancements in treating patients with brain metastases.
This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.
O’Shaughnessy and McArthur discuss recent advancements in the treatment of brain metastases in HER2-positive breast cancer. McArthur highlights subgroup analyses from the HER2CLIMB trial, revealing a significant survival advantage of the tucatinib-containing regimen, particularly in patients with brain metastases. She emphasizes the paradigm-shifting impact of this data on treatment approaches. Additionally, the TUXEDO phase 2 trial explores the efficacy of trastuzumab deruxtecan (T-DXd) in patients with active brain metastases, showing impressive progression-free survival of nearly 2 years in a high-risk population. The I-ROSETTE study from a Japanese group evaluates T-DXd in patients with leptomeningeal disease, demonstrating promising overall survival rates. The discussion underscores the evolving landscape of HER2-positive breast cancer treatment, with emerging strategies addressing the unmet needs of patients with brain and leptomeningeal involvement.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
